Zhitong Finance App News, China Regenerative Medicine (08158.HK) announced that on January 2, 2026, China Regeneration (Hong Kong) Investment Co., Ltd. (a wholly-owned subsidiary of the Company) and China Star Entertainment (BVI) Limited (China Star Group Limited (a company listed on the main board of the Hong Kong Stock Exchange Limited (stock code: 0326)) entered into a sales agreement. China Regeneration (Hong Kong) agreed to At a cost of HK$5,500, it acquired 55% of the shares of Kangmeizan Biotechnology Development Co., Ltd. (formerly Hong Kong Dippenny Culture Media Co., Ltd.) (a wholly-owned subsidiary of China Star). After the acquisition is completed, China Regeneration (Hong Kong) and China Star will hold 55% and 45% of Kang Meizan's shares respectively. Transactions under the sales agreement are completed simultaneously.

Zhitongcaijing · 4d ago
Zhitong Finance App News, China Regenerative Medicine (08158.HK) announced that on January 2, 2026, China Regeneration (Hong Kong) Investment Co., Ltd. (a wholly-owned subsidiary of the Company) and China Star Entertainment (BVI) Limited (China Star Group Limited (a company listed on the main board of the Hong Kong Stock Exchange Limited (stock code: 0326)) entered into a sales agreement. China Regeneration (Hong Kong) agreed to At a cost of HK$5,500, it acquired 55% of the shares of Kangmeizan Biotechnology Development Co., Ltd. (formerly Hong Kong Dippenny Culture Media Co., Ltd.) (a wholly-owned subsidiary of China Star). After the acquisition is completed, China Regeneration (Hong Kong) and China Star will hold 55% and 45% of Kang Meizan's shares respectively. Transactions under the sales agreement are completed simultaneously.